应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
ARGX Argenx SE
未开盘 01-27 16:00:00 EST
864.42
+31.26
+3.75%
盘后
864.42
+0.00
0.00%
17:23 EST
最高
881.89
最低
845.88
成交量
63.43万
今开
845.88
昨收
833.16
日振幅
4.32%
总市值
534.93亿
流通市值
528.73亿
总股本
6,188万
成交额
5.51亿
换手率
1.04%
流通股本
6,117万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
财报前瞻|Argenx SE本季度营收预计增0.82,机构观点偏乐观
财报Agent · 01-05
财报前瞻|Argenx SE本季度营收预计增0.82,机构观点偏乐观
明星药物遭重挫!Argenx终止甲状腺眼病药物试验
智通财经 · 2025-12-15
明星药物遭重挫!Argenx终止甲状腺眼病药物试验
Argenx Se涨1.03% 股价突破900美元大关
市场透视 · 2025-11-14
Argenx Se涨1.03% 股价突破900美元大关
Argenx Se涨0.32% 股价突破800美元大关
市场透视 · 2025-10-09
Argenx Se涨0.32% 股价突破800美元大关
Argenx Se8月11日成交额为4.25亿美元
市场透视 · 2025-08-12
Argenx Se8月11日成交额为4.25亿美元
Argenx Se8月8日成交额为1.88亿美元
市场透视 · 2025-08-09
Argenx Se8月8日成交额为1.88亿美元
Argenx Se2025财年第二财季实现净利润4.18亿美元,同比增加1386.95%
市场透视 · 2025-08-09
Argenx Se2025财年第二财季实现净利润4.18亿美元,同比增加1386.95%
Argenx Se8月6日成交额为2.77亿美元
市场透视 · 2025-08-07
Argenx Se8月6日成交额为2.77亿美元
Argenx Se8月5日成交额为3.26亿美元
市场透视 · 2025-08-06
Argenx Se8月5日成交额为3.26亿美元
Argenx Se8月4日成交额为2.81亿美元
市场透视 · 2025-08-05
Argenx Se8月4日成交额为2.81亿美元
Argenx Se8月1日成交额为4.26亿美元
市场透视 · 2025-08-02
Argenx Se8月1日成交额为4.26亿美元
富国银行:维持argenx(ARGX.US)评级,由增持调整至增持评级, 目标价由723.00美元调整至741.00美元。
金融界 · 2025-03-01
富国银行:维持argenx(ARGX.US)评级,由增持调整至增持评级, 目标价由723.00美元调整至741.00美元。
Citizens Capital Markets:维持argenx(ARGX.US)评级,由优于大市调整至优于大市评级, 目标价由696.00美元调整至701.00美元。
金融界 · 2025-02-28
Citizens Capital Markets:维持argenx(ARGX.US)评级,由优于大市调整至优于大市评级, 目标价由696.00美元调整至701.00美元。
argenx 2024年第四季度GAAP每股收益$11.79,同比增长至$(1.68);销售额$7.6122亿,高于$7.0628亿预期
财报速递 · 2025-02-27
argenx 2024年第四季度GAAP每股收益$11.79,同比增长至$(1.68);销售额$7.6122亿,高于$7.0628亿预期
特朗普2.0时代即将开启,投资机会如何掘金?
招商基金 · 2025-01-20
特朗普2.0时代即将开启,投资机会如何掘金?
HC Wainwright & Co.:重申argenx(ARGX.US)评级,由买入调整至买入评级, 目标价由670.00美元调整至717.00美元。
金融界 · 2025-01-15
HC Wainwright & Co.:重申argenx(ARGX.US)评级,由买入调整至买入评级, 目标价由670.00美元调整至717.00美元。
Truist Securities:重申argenx(ARGX.US)评级,由买入调整至买入评级, 目标价由660.00美元调整至700.00美元。
金融界 · 2025-01-14
Truist Securities:重申argenx(ARGX.US)评级,由买入调整至买入评级, 目标价由660.00美元调整至700.00美元。
Piper Sandler:维持argenx(ARGX.US)评级,由增持调整至增持评级, 目标价由620.00美元调整至725.00美元。
金融界 · 2025-01-07
Piper Sandler:维持argenx(ARGX.US)评级,由增持调整至增持评级, 目标价由620.00美元调整至725.00美元。
Argenx Se盘中异动 临近午盘股价大涨5.08%报638.07美元
市场透视 · 2024-12-17
Argenx Se盘中异动 临近午盘股价大涨5.08%报638.07美元
纳斯达克100指数年度调整在即!这11家公司或迎来股价飙升机会
老虎资讯综合 · 2024-12-13
纳斯达克100指数年度调整在即!这11家公司或迎来股价飙升机会
加载更多
公司概况
公司名称:
Argenx SE
所属市场:
NASDAQ
上市日期:
--
主营业务:
Argenx Se根据荷兰法律于2008年4月25日成立,是一家私人有限责任公司(besloten vennootschap met beperkte aansprakelijkheid)。 于2014年5月28日,根据公证转换契约及修订,该公司转为上市有限责任公司(naamloze vennootschap)。 该公司是一家处于商业阶段的、全球性的、完全整合的生物制药公司,开发用于治疗严重自身免疫性疾病的差异化疗法。
发行价格:
--
{"stockData":{"symbol":"ARGX","market":"US","secType":"STK","nameCN":"Argenx SE","latestPrice":864.42,"timestamp":1769547600000,"preClose":833.16,"halted":0,"volume":634348,"hourTrading":{"tag":"盘后","latestPrice":864.42,"preClose":864.42,"latestTime":"17:23 EST","volume":9547,"amount":8252618.74,"timestamp":1769552621246,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.037519804119256796,"floatShares":61166252,"shares":61883400,"eps":23.271248,"marketStatus":"未开盘","change":31.26,"latestTime":"01-27 16:00:00 EST","open":845.88,"high":881.89,"low":845.88,"amount":550684260.9496801,"amplitude":0.043221,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":23.271248,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1769590800000},"marketStatusCode":0,"adr":1,"adrRate":1,"listingDate":1495080000000,"exchange":"NASDAQ","adjPreClose":833.16,"preHourTrading":{"tag":"盘前","latestPrice":848.49,"preClose":833.16,"latestTime":"09:29 EST","volume":1282,"amount":1084529.1812,"timestamp":1769524199104,"change":15.33,"changeRate":0.0184,"amplitude":0.011162},"postHourTrading":{"tag":"盘后","latestPrice":864.42,"preClose":864.42,"latestTime":"17:23 EST","volume":9547,"amount":8252618.74,"timestamp":1769552621246,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.613186,"impliedVol":0.3554,"impliedVolPercentile":0.5896},"requestUrl":"/m/hq/s/ARGX","defaultTab":"news","newsList":[{"id":"1125206528","title":"财报前瞻|Argenx SE本季度营收预计增0.82,机构观点偏乐观","url":"https://stock-news.laohu8.com/highlight/detail?id=1125206528","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125206528?lang=zh_cn&edition=full","pubTime":"2026-01-05 10:00","pubTimestamp":1767578435,"startTime":"0","endTime":"0","summary":"Argenx SE将于2026年01月12日发布最新季度财报,市场关注本季度收入与盈利的持续改善、核心产品放量与费用效率的平衡。市场一致预期显示,本季度Argenx SE总收入预计为12.83亿美元,同比增长81.79%;毛利率预计维持高位;净利率与归母净利润走势改善;调整后每股收益预计为5.77美元,同比增长3.38%。上季度Argenx SE实现营收11.51亿美元,同比增长95.51%;毛利率59.61%;归属母公司净利润3.44亿美元,净利率29.90%,环比增长40.31%;调整后每股收益5.18美元,同比增长2.73%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻|Argenx SE本季度营收预计增0.82,机构观点偏乐观","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARGX"],"gpt_icon":0},{"id":"2591436776","title":"明星药物遭重挫!Argenx终止甲状腺眼病药物试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2591436776","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591436776?lang=zh_cn&edition=full","pubTime":"2025-12-15 19:32","pubTimestamp":1765798348,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,比利时生物技术公司Argenx SE表示将终止治疗影响眼睛的自免疫疾病实验药物的后期试验后,其股价创下七个月来最大跌幅。Argenx表示,基于独立数据监测委员会的建议,正在中重度甲状腺眼病成人患者中进行评估的药物Efgartigimod将停止试验。该公司股价在布鲁塞尔股市一度下跌9.7%,为5月8日以来最大跌幅。Argenx预计明年将公布针对多种自免疫疾病的其他四项后期临床试验项目的结果,其中三项涉及Vyvgart。","market":"us","thumbnail":"https://static.tigerbbs.com/c7da52addfd52fb216bcf87283f43750","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/c7da52addfd52fb216bcf87283f43750"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1381720.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"明星药物遭重挫!Argenx终止甲状腺眼病药物试验","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1983260115.SGD","ARGX","IE00BJT1NW94.SGD","IE00B4R5TH58.HKD","BK4585","BK4588","IE00B2B36J28.USD","LU2324357040.USD","IE00BJJMRZ35.SGD","IE00BFTCPJ56.SGD","IE0009355771.USD","IE0034235188.USD","IE0002141913.USD","LU0109394709.USD","BK4139","BK4505","LU0320765992.SGD","LU0889565916.HKD"],"gpt_icon":0},{"id":"2583633533","title":"Argenx Se涨1.03% 股价突破900美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2583633533","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583633533?lang=zh_cn&edition=full","pubTime":"2025-11-14 22:52","pubTimestamp":1763131945,"startTime":"0","endTime":"0","summary":"北京时间2025年11月14日22时52分,Argenx Se股票出现异动,股价急速拉升1.03%。Argenx Se股票所在的生物技术行业中,整体涨幅为0.64%。Argenx Se公司简介:Argenx是一家荷兰生物制药公司,专注于开发针对罕见自身免疫性疾病的基于抗体的疗法。2022年,Argenx还获得了Vyvgart皮下制剂Vyvgart Hytrulo的FDA批准,与Vyvgart的静脉给药相比,这是一种更方便的选择。2024年,FDA批准Vyvgart Hytrulo用于治疗慢性炎症性脱髓鞘多神经病变,这是一种罕见的免疫介导的周围神经系统神经肌肉疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251114225226a6f9cd08&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251114225226a6f9cd08&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","IE0009355771.USD","BK4588","LU0109394709.USD","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","IE00BFTCPJ56.SGD","LU0889565916.HKD","BK4505","IE00B4R5TH58.HKD","IE0034235188.USD","IE00BJT1NW94.SGD","LU2324357040.USD","IE0002141913.USD","ARGX","BK4139","LU0320765992.SGD"],"gpt_icon":0},{"id":"2574113514","title":"Argenx Se涨0.32% 股价突破800美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2574113514","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574113514?lang=zh_cn&edition=full","pubTime":"2025-10-09 21:32","pubTimestamp":1760016729,"startTime":"0","endTime":"0","summary":"北京时间2025年10月09日21时32分,Argenx Se股票出现异动,股价急速拉升0.32%。Argenx Se股票所在的生物技术行业中,整体跌幅为0.15%。Argenx Se公司简介:Argenx是一家荷兰生物制药公司,专注于开发针对罕见自身免疫性疾病的基于抗体的疗法。2022年,Argenx还获得了Vyvgart皮下制剂Vyvgart Hytrulo的FDA批准,与Vyvgart的静脉给药相比,这是一种更方便的选择。2024年,FDA批准Vyvgart Hytrulo用于治疗慢性炎症性脱髓鞘多神经病变,这是一种罕见的免疫介导的周围神经系统神经肌肉疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251009213209a6b1f8ea&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251009213209a6b1f8ea&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","IE00B4R5TH58.HKD","IE0009355771.USD","LU0320765992.SGD","IE00BJT1NW94.SGD","IE0002141913.USD","IE00BFTCPJ56.SGD","BK4588","BK4139","IE00B2B36J28.USD","LU2324357040.USD","BK4585","LU0889565916.HKD","IE00BJJMRZ35.SGD","ARGX","LU0109394709.USD"],"gpt_icon":0},{"id":"2558917536","title":"Argenx Se8月11日成交额为4.25亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2558917536","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558917536?lang=zh_cn&edition=full","pubTime":"2025-08-12 09:18","pubTimestamp":1754961500,"startTime":"0","endTime":"0","summary":"美东时间2025年8月11日,Argenx Se成交额为4.25亿美元,成交额较昨日增加125.83%,当日成交量为66.25万股。Argenx Se于2025年8月11日跌3.46%,报638.9美元,该股过去5个交易日跌7.45%,年初至今涨3.89%,过去60日涨20.03%。2022年,Argenx还获得了Vyvgart皮下制剂Vyvgart Hytrulo的FDA批准,与Vyvgart的静脉给药相比,这是一种更方便的选择。2024年,FDA批准Vyvgart Hytrulo用于治疗慢性炎症性脱髓鞘多神经病变,这是一种罕见的免疫介导的周围神经系统神经肌肉疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250812091832a482e303&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250812091832a482e303&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","LU0889565916.HKD","BK4585","ARGX","IE0002141913.USD","IE00BJT1NW94.SGD","BK4505","BK4588","LU0109394709.USD","IE0009355771.USD","IE00B4R5TH58.HKD","IE00B2B36J28.USD","LU0320765992.SGD"],"gpt_icon":0},{"id":"2558508707","title":"Argenx Se8月8日成交额为1.88亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2558508707","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558508707?lang=zh_cn&edition=full","pubTime":"2025-08-09 09:18","pubTimestamp":1754702305,"startTime":"0","endTime":"0","summary":"美东时间2025年8月8日,Argenx Se成交额为1.88亿美元,成交额较昨日减少15.90%,当日成交量为28.37万股。Argenx Se于2025年8月8日跌1.56%,报661.83美元,该股过去5个交易日跌1.78%,年初至今涨7.61%,过去60日涨22.0%。2022年,Argenx还获得了Vyvgart皮下制剂Vyvgart Hytrulo的FDA批准,与Vyvgart的静脉给药相比,这是一种更方便的选择。2024年,FDA批准Vyvgart Hytrulo用于治疗慢性炎症性脱髓鞘多神经病变,这是一种罕见的免疫介导的周围神经系统神经肌肉疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250809091837a47e1c51&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250809091837a47e1c51&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00B4R5TH58.HKD","ARGX","BK4505","IE00BJT1NW94.SGD","IE00B2B36J28.USD","LU0109394709.USD","LU0320765992.SGD","LU0889565916.HKD","IE00BFTCPJ56.SGD","BK4585","BK4588","BK4139","IE0002141913.USD","IE0009355771.USD","IE00BJJMRZ35.SGD"],"gpt_icon":0},{"id":"2558575425","title":"Argenx Se2025财年第二财季实现净利润4.18亿美元,同比增加1386.95%","url":"https://stock-news.laohu8.com/highlight/detail?id=2558575425","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558575425?lang=zh_cn&edition=full","pubTime":"2025-08-09 00:00","pubTimestamp":1754668827,"startTime":"0","endTime":"0","summary":"8月9日,Argenx Se公布财报,公告显示公司2025财年第二财季净利润为4.18亿美元,同比增加1386.95%;其中营业收入为17.53亿美元,同比增加99.89%,每股基本收益为6.85美元。从资产负债表来看,Argenx Se总负债10.80亿美元,其中短期债务7.58百万美元,资产负债比为6.65,流动比率为5.60。机构评级:截至2025年8月9日,当前有32家机构对Argenx Se目标价做出预测,其中目标均价为805.07美元,其中最低目标价为700.00美元,最高目标价为1070.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250809000034a6db5589&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250809000034a6db5589&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ARGX"],"gpt_icon":0},{"id":"2557581446","title":"Argenx Se8月6日成交额为2.77亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2557581446","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557581446?lang=zh_cn&edition=full","pubTime":"2025-08-07 09:18","pubTimestamp":1754529505,"startTime":"0","endTime":"0","summary":"美东时间2025年8月6日,Argenx Se成交额为2.77亿美元,成交额较昨日减少14.97%,当日成交量为41.08万股。Argenx Se于2025年8月6日跌0.26%,报673.15美元,该股过去5个交易日涨12.4%,年初至今涨9.46%,过去60日涨22.47%。2022年,Argenx还获得了Vyvgart皮下制剂Vyvgart Hytrulo的FDA批准,与Vyvgart的静脉给药相比,这是一种更方便的选择。2024年,FDA批准Vyvgart Hytrulo用于治疗慢性炎症性脱髓鞘多神经病变,这是一种罕见的免疫介导的周围神经系统神经肌肉疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250807091827a6d78e9f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250807091827a6d78e9f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","BK4585","BK4588","ARGX","LU0109394709.USD","BK4139","LU0320765992.SGD","LU0889565916.HKD"],"gpt_icon":0},{"id":"2557345798","title":"Argenx Se8月5日成交额为3.26亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2557345798","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557345798?lang=zh_cn&edition=full","pubTime":"2025-08-06 09:18","pubTimestamp":1754443089,"startTime":"0","endTime":"0","summary":"美东时间2025年8月5日,Argenx Se成交额为3.26亿美元,成交额较昨日增加16.07%,当日成交量为47.63万股。Argenx Se于2025年8月5日跌2.23%,报674.9美元,该股过去5个交易日涨12.71%,年初至今涨9.74%,过去60日涨18.59%。2022年,Argenx还获得了Vyvgart皮下制剂Vyvgart Hytrulo的FDA批准,与Vyvgart的静脉给药相比,这是一种更方便的选择。2024年,FDA批准Vyvgart Hytrulo用于治疗慢性炎症性脱髓鞘多神经病变,这是一种罕见的免疫介导的周围神经系统神经肌肉疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250806091812a4778a4e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250806091812a4778a4e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","BK4139","LU0320765992.SGD","BK4585","LU0109394709.USD","LU0889565916.HKD","BK4588","ARGX"],"gpt_icon":0},{"id":"2557356590","title":"Argenx Se8月4日成交额为2.81亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2557356590","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557356590?lang=zh_cn&edition=full","pubTime":"2025-08-05 09:18","pubTimestamp":1754356683,"startTime":"0","endTime":"0","summary":"美东时间2025年8月4日,Argenx Se成交额为2.81亿美元,成交额较昨日减少34.11%,当日成交量为41.10万股。Argenx Se于2025年8月4日涨2.45%,报690.32美元,该股过去5个交易日涨15.98%,年初至今涨12.25%,过去60日涨10.82%。2022年,Argenx还获得了Vyvgart皮下制剂Vyvgart Hytrulo的FDA批准,与Vyvgart的静脉给药相比,这是一种更方便的选择。2024年,FDA批准Vyvgart Hytrulo用于治疗慢性炎症性脱髓鞘多神经病变,这是一种罕见的免疫介导的周围神经系统神经肌肉疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250805091809a4756520&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250805091809a4756520&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LU0109394709.USD","BK4505","BK4585","BK4588","LU0320765992.SGD","LU0889565916.HKD","ARGX"],"gpt_icon":0},{"id":"2556484478","title":"Argenx Se8月1日成交额为4.26亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2556484478","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2556484478?lang=zh_cn&edition=full","pubTime":"2025-08-02 09:17","pubTimestamp":1754097473,"startTime":"0","endTime":"0","summary":"美东时间2025年8月1日,Argenx Se成交额为4.26亿美元,成交额较昨日减少54.27%,当日成交量为63.36万股。Argenx Se于2025年8月1日涨0.52%,报673.8美元,该股过去5个交易日涨13.82%,年初至今涨9.56%,过去60日涨9.54%。2022年,Argenx还获得了Vyvgart皮下制剂Vyvgart Hytrulo的FDA批准,与Vyvgart的静脉给药相比,这是一种更方便的选择。2024年,FDA批准Vyvgart Hytrulo用于治疗慢性炎症性脱髓鞘多神经病变,这是一种罕见的免疫介导的周围神经系统神经肌肉疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250802091755a6ce9d78&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250802091755a6ce9d78&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0320765992.SGD","BK4139","BK4588","BK4505","LU0889565916.HKD","BK4585","ARGX","LU0109394709.USD"],"gpt_icon":0},{"id":"2516390377","title":"富国银行:维持argenx(ARGX.US)评级,由增持调整至增持评级, 目标价由723.00美元调整至741.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2516390377","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516390377?lang=zh_cn&edition=full","pubTime":"2025-03-01 01:31","pubTimestamp":1740763885,"startTime":"0","endTime":"0","summary":"富国银行:维持argenx(ARGX.US)评级,由增持调整至增持评级, 目标价由723.00美元调整至741.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/01013148469987.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["ARGX"],"gpt_icon":0},{"id":"2514337690","title":"Citizens Capital Markets:维持argenx(ARGX.US)评级,由优于大市调整至优于大市评级, 目标价由696.00美元调整至701.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514337690","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514337690?lang=zh_cn&edition=full","pubTime":"2025-02-28 23:41","pubTimestamp":1740757319,"startTime":"0","endTime":"0","summary":"Citizens Capital Markets:维持argenx(ARGX.US)评级,由优于大市调整至优于大市评级, 目标价由696.00美元调整至701.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/28234148468149.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["ARGX"],"gpt_icon":0},{"id":"1142674592","title":"argenx 2024年第四季度GAAP每股收益$11.79,同比增长至$(1.68);销售额$7.6122亿,高于$7.0628亿预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1142674592","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142674592?lang=zh_cn&edition=full","pubTime":"2025-02-27 14:22","pubTimestamp":1740637328,"startTime":"0","endTime":"0","summary":"argenx公布季度每股收益为$11.79。公司季度销售额为$7.6122亿,超过分析师一致预期的$7.0628亿,超出7.78%。与去年同期$4.1784亿销售额相比,同比增长了82.18%。以上内容来自Benzinga Earnings专栏,原文如下:argenx reported quarterly earnings of $11.79 per share. This is a 801.79 percent increase over losses of $ per share from the same period last year. The company reported quarterly sales of $761.22 million which beat the analyst consensus estimate of $706.28 million by 7.78 percent. This is a 82.18 percent increase over sales of $417.84 million the same period last ye","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"argenx 2024年第四季度GAAP每股收益$11.79,同比增长至$(1.68);销售额$7.6122亿,高于$7.0628亿预期","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARGX"],"gpt_icon":0},{"id":"2504449484","title":"特朗普2.0时代即将开启,投资机会如何掘金?","url":"https://stock-news.laohu8.com/highlight/detail?id=2504449484","media":"招商基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2504449484?lang=zh_cn&edition=full","pubTime":"2025-01-20 10:36","pubTimestamp":1737340585,"startTime":"0","endTime":"0","summary":"美国候任总统唐纳德·特朗普将于美东时间1月20日12时正式宣誓就任美国第47任总统。特朗普2.0时代即将开启,有哪些投资机会可以布局?值得一提的是,科技股在特朗普任期内表现尤为突出,成为推动美股上涨的主要力量。在特朗普第一个任期内,美元整体表现相对弱势。4年任期内,美元指数累计下跌了10.53%。而纵观全球市场,在特朗普上一任期内,恒生科技指数涨幅超过147%,表现甚至略微优于纳斯达克指数。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250120103318abb12e8e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250120103318abb12e8e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RYAAY","TSLA","LNT","AFRM","NQmain","GILD","GRAB","ALAB","SMCI","HLNE","ITCI","QID","LKQ","FSV","FCNCA","NICE","AKAM","CINF","CEG","DASH","HTHT","MPWR","NDSN","PFG","TQQQ","LULU","ON","TCOM","MNDY","CSX","ZM","PODD","LSTR","INCY","PLTR","MTSI","TEAM","DOCU","KDP","GEN","RKLB","DPZ","TSCO","AAL","INTC","ODFL","ROP","MRNA","TPG","CHDN","RGEN","OLED","ROKU","SQQQ","GEHC","TMUS","BK4534","FFIV","PAYX","COIN","WDC","SFM","TTWO","EXPE","CTSH","FOXA","MSFT","ADSK","BSY","BPOP","TSYW.SI","HON","MCHP","AXON","FOX","ADI","LU0757428866.USD","FSLR","FTNT","INTU","LU1815336091.USD","TSEM","OTEX","WWD","CHTR","ORLY","QCOM","CASY","CTAS","PNFP","AZN","MDLZ","FWONK","ILMN","FRPT","DLTR","SBAC","TECH","LU0053671581.USD","EVRG","POOL","BK4561","BKNG","HSIC","RADX","FAST","ANSS","COKE","CWST","QLD","RPRX","JBHT","SIRI","ONC","TRMB","PCVX","NVIW.SI","GOOGL","LECO","TXN","ENTG","JD","ULTA","NXPI","CHKP","BK4593","LOGI","SBUX","EBAY","LI","CFLT","DKNG","DOX","MARA","WYNN","EXE","MIDD","PTC","ROIV","ZS","WBA","AGNC","NFLX","BK4086","ASML","LSCC","LU2065731478.USD","TROW","ESLT","ISRG","AAPL","SNPS","AAON","SOFI","ERIC","AMZN","MTCH","NDAQ","STLD","QQQ","GTLB","DDOG","TTD","USAW.SI","MRVL","FYBR","DSGX","SEIC","CPB","OKTA","AUR","COO","CYBR","CPRT","SRPT","WTFC","HQY","CBSH","CME","MNST","DUOL","PEP","COST","PCAR","CHRW","MANH","NTES","ARM","ARGX","TER","AMAT","MEDP","NTRA","EXAS","ICLR","GMAB","AVGO","CG","LIN","REG","NTNX","META","SAIA","TTEK","SSNC","STX","NBIX","Z","MKSI","BK4588","BIIB","MDB","HOLX","PARA","QRVO","NTAP","PCTY","QXO","APA","BK4585","IDXX","CDNS","NWSA","BK4581",".IXIC","HBAN","AEP","FTAI","RGLD","KHC","HST","BRKR","BMRN","CCEP","FER","HOOD","MKTX","PSQ","CZR","GNTX","CRWD","RVMD","BKR","CDW","JKHY","ROST","AMGN","CSCO","EQIX","CSGP","NVMI","REGN","TW","USJW.SI","LNW","CSWI","GLPI","EA","PDD","SWKS","ENPH","ALNY","MELI","ADBE","EWBC","PAA","MNQmain","MMYT","BK4550","INSM","LAMR","NTRS","NVDA","LPLA","RIVN","ERIE","CHRD","ALGN","TLN","BPMC","AMD"],"gpt_icon":1},{"id":"2503501033","title":"HC Wainwright & Co.:重申argenx(ARGX.US)评级,由买入调整至买入评级, 目标价由670.00美元调整至717.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2503501033","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2503501033?lang=zh_cn&edition=full","pubTime":"2025-01-15 01:34","pubTimestamp":1736876047,"startTime":"0","endTime":"0","summary":"HC Wainwright & Co.:重申argenx(ARGX.US)评级,由买入调整至买入评级, 目标价由670.00美元调整至717.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/01/15013447459172.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["ARGX"],"gpt_icon":0},{"id":"2503570065","title":"Truist Securities:重申argenx(ARGX.US)评级,由买入调整至买入评级, 目标价由660.00美元调整至700.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2503570065","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2503570065?lang=zh_cn&edition=full","pubTime":"2025-01-14 23:50","pubTimestamp":1736869851,"startTime":"0","endTime":"0","summary":"Truist Securities:重申argenx(ARGX.US)评级,由买入调整至买入评级, 目标价由660.00美元调整至700.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/01/14235047458887.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["ARGX"],"gpt_icon":0},{"id":"2501027552","title":"Piper Sandler:维持argenx(ARGX.US)评级,由增持调整至增持评级, 目标价由620.00美元调整至725.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2501027552","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2501027552?lang=zh_cn&edition=full","pubTime":"2025-01-07 22:12","pubTimestamp":1736259157,"startTime":"0","endTime":"0","summary":"Piper Sandler:维持argenx(ARGX.US)评级,由增持调整至增持评级, 目标价由620.00美元调整至725.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/01/07221247232536.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["ARGX"],"gpt_icon":0},{"id":"2492116716","title":"Argenx Se盘中异动 临近午盘股价大涨5.08%报638.07美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2492116716","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492116716?lang=zh_cn&edition=full","pubTime":"2024-12-17 00:42","pubTimestamp":1734367343,"startTime":"0","endTime":"0","summary":"北京时间2024年12月17日00时42分,Argenx Se股票出现异动,股价快速上涨5.08%。截至发稿,该股报638.07美元/股,成交量11.2229万股,换手率0.19%,振幅3.29%。机构评级方面,在所有33家参与评级的机构中,88%的券商给予买入建议,12%的券商给予持有建议,无券商给予卖出建议。Argenx Se股票所在的生物技术行业中,整体涨幅为0.68%。Argenx Se公司简介:Argenx是一家荷兰公司,专注于利用其抗体工程技术治疗罕见的自身免疫性疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241217004223984c7389&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241217004223984c7389&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0320765992.SGD","LU0109394709.USD","BK4585","LU0889565916.HKD","BK4505","BK4139","BK4588","ARGX"],"gpt_icon":0},{"id":"1171249240","title":"纳斯达克100指数年度调整在即!这11家公司或迎来股价飙升机会","url":"https://stock-news.laohu8.com/highlight/detail?id=1171249240","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1171249240?lang=zh_cn&edition=full","pubTime":"2024-12-13 11:20","pubTimestamp":1734060022,"startTime":"0","endTime":"0","summary":"在今年年底的指数重组中,也可能有一些公司会被从纳斯达克100指数中移除。纳斯达克预计将在周五宣布纳斯达克100指数的变化,这对获得入选资格的公司来说不仅仅是声望问题。当宣布这一计划时,Palantir表示预期将被纳入纳斯达克100,其股价随之上涨。在纳斯达克100指数的现有成分股中,有11家公司截至11月30日的市值未进入纳斯达克综合指数的前100家非金融公司,因此可能会被移除。","market":"us","thumbnail":"https://static.tigerbbs.com/44fc2c33800eae6e4f0bbec10e83a1a5","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/44fc2c33800eae6e4f0bbec10e83a1a5"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"39abcfe8de64da946c6d53e578899b57","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"纳指100年度调整在即!这11家公司或迎来股价飙升机会","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AXON","TCOM","ALNY","MSTR","ARGX","EQIX","PLTR","NTES","SNY","JD","UAL"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.argenx.com","stockEarnings":[{"period":"1week","weight":0.0677},{"period":"1month","weight":0.0231},{"period":"3month","weight":0.0516},{"period":"6month","weight":0.2895},{"period":"1year","weight":0.3323},{"period":"ytd","weight":0.0279}],"compareEarnings":[{"period":"1week","weight":0.0264},{"period":"1month","weight":0.0075},{"period":"3month","weight":0.0118},{"period":"6month","weight":0.1003},{"period":"1year","weight":0.1604},{"period":"ytd","weight":0.0199}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Argenx Se根据荷兰法律于2008年4月25日成立,是一家私人有限责任公司(besloten vennootschap met beperkte aansprakelijkheid)。 于2014年5月28日,根据公证转换契约及修订,该公司转为上市有限责任公司(naamloze vennootschap)。 该公司是一家处于商业阶段的、全球性的、完全整合的生物制药公司,开发用于治疗严重自身免疫性疾病的差异化疗法。","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.011084},{"month":2,"riseRate":0.375,"avgChangeRate":0.041314},{"month":3,"riseRate":0.5,"avgChangeRate":-0.018965},{"month":4,"riseRate":0.75,"avgChangeRate":0.033039},{"month":5,"riseRate":0.5,"avgChangeRate":0.060079},{"month":6,"riseRate":0.777778,"avgChangeRate":0.053836},{"month":7,"riseRate":0.666667,"avgChangeRate":0.0867},{"month":8,"riseRate":0.666667,"avgChangeRate":0.01751},{"month":9,"riseRate":0.444444,"avgChangeRate":-0.022149},{"month":10,"riseRate":0.666667,"avgChangeRate":0.037064},{"month":11,"riseRate":0.777778,"avgChangeRate":0.116374},{"month":12,"riseRate":0.444444,"avgChangeRate":0.116024}],"exchange":"NASDAQ","name":"Argenx SE","nameEN":"Argenx SE"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Argenx SE(ARGX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Argenx SE(ARGX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Argenx SE,ARGX,Argenx SE股票,Argenx SE股票老虎,Argenx SE股票老虎国际,Argenx SE行情,Argenx SE股票行情,Argenx SE股价,Argenx SE股市,Argenx SE股票价格,Argenx SE股票交易,Argenx SE股票购买,Argenx SE股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Argenx SE(ARGX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Argenx SE(ARGX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}